Cargando…

Racial/ethnic disparities on inflammation and response to methylprednisolone in severe COVID-19 pneumonia

BACKGROUND: Racial/ethnic minorities are at higher risk for severe COVID-19. This may be related to social determinants that lead to chronic inflammatory states. The aims of the study were to determine if there are racial/ethnic disparities with inflammatory markers and association of methylpredniso...

Descripción completa

Detalles Bibliográficos
Autores principales: Go, Ronaldo C., Nyirenda, Themba, Bojarian, Maryam, Hosseini, Davood K., Kim, Kevin, Rahim, Mehek, Paleoudis, Elli G., Go, Anna C., Han, Zhiyong, Sperber, Steven J., Gupta, Anjali
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8919360/
https://www.ncbi.nlm.nih.gov/pubmed/35287602
http://dx.doi.org/10.1186/s12879-022-07237-1
_version_ 1784668929581383680
author Go, Ronaldo C.
Nyirenda, Themba
Bojarian, Maryam
Hosseini, Davood K.
Kim, Kevin
Rahim, Mehek
Paleoudis, Elli G.
Go, Anna C.
Han, Zhiyong
Sperber, Steven J.
Gupta, Anjali
author_facet Go, Ronaldo C.
Nyirenda, Themba
Bojarian, Maryam
Hosseini, Davood K.
Kim, Kevin
Rahim, Mehek
Paleoudis, Elli G.
Go, Anna C.
Han, Zhiyong
Sperber, Steven J.
Gupta, Anjali
author_sort Go, Ronaldo C.
collection PubMed
description BACKGROUND: Racial/ethnic minorities are at higher risk for severe COVID-19. This may be related to social determinants that lead to chronic inflammatory states. The aims of the study were to determine if there are racial/ethnic disparities with inflammatory markers and association of methylprednisolone to in hospital survival. METHODS: This was a secondary analysis of a retrospective cohort study of patients ≥ 18 years of age and admitted for severe COVID-19 pneumonia between March and June 2020 in 13 Hospitals in New Jersey, United States. Patients who received other formulation of corticosteroids were not included. Area under the receiver operating characteristics curves were performed to test for discriminatory ability of each inflammatory makers. Univariate and multivariate Cox regression assessed the association of variables to in hospital survival. RESULTS: Propensity matched sample (n = 759) between no methylprednisolone (n = 380) and methylprednisolone (n = 379) had 338 Whites, 102 Blacks, 61 Asian/Indians, and 251 non-Black non-White Hispanics. Compared to CRP, area under receiving operating characteristic curve for d-dimer in Hispanics (0.742) was statistically different (DeLong Test P = 0.0041). Multivariate cox regression showed that different variables in Blacks [age ≥ 60 years (HR = 3.71, P = 0.0281), mechanical ventilation (HR = 5.07, P = 0.0281) and creatinine ≥ 1.5 mg/dL (HR = 3.61, P = 0.0007)], Whites [cancer (HR = 1.68, P = 0.0213), qSOFA score of 1 (HR = 1.81, P = 0.0213), qSOFA score of 2 (HR = 5.16, P < 0.0001), qSOFA score of 3 (HR = 11.81, P < 0.0001) and creatinine ≥ 1.5 mg/dL (HR = 2.16, P = 0.0006)], Hispanics [hypertension (HR = 2.52, P = 0.0007), cancer (HR = 2.99, P = 0.0244 and D-dimer ≥ 2 mcg/mL (HR = 2.22, P = 0.0077)], and Asian/Indians [ chronic kidney disease (HR = 6.36, P = 0.0031) and CRP > 20 mg/L (HR = 5.02, P = 0.0032)] were statistically significant for mortality. Low dose and high dose methylprednisolone were significantly associated with prolonged survival in Whites [low dose (HR = 0.37, P < 0.0001) and high dose (HR = 0.48, P < 0.0183)] and Asian/Indians [low dose (HR = 0.13, P = 0.0101) and high dose (HR = 0.15, P = 0.01)]. However, high dose was not associated with improved survival compared to low dose. Methylprednisolone was not associated with prolonged survival in Blacks and Hispanics. CONCLUSION: Racial/Ethnic disparities with inflammatory markers preclude the use of one marker as a predictor of survival. Methylprednisolone is associated with prolonged survival in Asian/Indians and Whites. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12879-022-07237-1.
format Online
Article
Text
id pubmed-8919360
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-89193602022-03-14 Racial/ethnic disparities on inflammation and response to methylprednisolone in severe COVID-19 pneumonia Go, Ronaldo C. Nyirenda, Themba Bojarian, Maryam Hosseini, Davood K. Kim, Kevin Rahim, Mehek Paleoudis, Elli G. Go, Anna C. Han, Zhiyong Sperber, Steven J. Gupta, Anjali BMC Infect Dis Research BACKGROUND: Racial/ethnic minorities are at higher risk for severe COVID-19. This may be related to social determinants that lead to chronic inflammatory states. The aims of the study were to determine if there are racial/ethnic disparities with inflammatory markers and association of methylprednisolone to in hospital survival. METHODS: This was a secondary analysis of a retrospective cohort study of patients ≥ 18 years of age and admitted for severe COVID-19 pneumonia between March and June 2020 in 13 Hospitals in New Jersey, United States. Patients who received other formulation of corticosteroids were not included. Area under the receiver operating characteristics curves were performed to test for discriminatory ability of each inflammatory makers. Univariate and multivariate Cox regression assessed the association of variables to in hospital survival. RESULTS: Propensity matched sample (n = 759) between no methylprednisolone (n = 380) and methylprednisolone (n = 379) had 338 Whites, 102 Blacks, 61 Asian/Indians, and 251 non-Black non-White Hispanics. Compared to CRP, area under receiving operating characteristic curve for d-dimer in Hispanics (0.742) was statistically different (DeLong Test P = 0.0041). Multivariate cox regression showed that different variables in Blacks [age ≥ 60 years (HR = 3.71, P = 0.0281), mechanical ventilation (HR = 5.07, P = 0.0281) and creatinine ≥ 1.5 mg/dL (HR = 3.61, P = 0.0007)], Whites [cancer (HR = 1.68, P = 0.0213), qSOFA score of 1 (HR = 1.81, P = 0.0213), qSOFA score of 2 (HR = 5.16, P < 0.0001), qSOFA score of 3 (HR = 11.81, P < 0.0001) and creatinine ≥ 1.5 mg/dL (HR = 2.16, P = 0.0006)], Hispanics [hypertension (HR = 2.52, P = 0.0007), cancer (HR = 2.99, P = 0.0244 and D-dimer ≥ 2 mcg/mL (HR = 2.22, P = 0.0077)], and Asian/Indians [ chronic kidney disease (HR = 6.36, P = 0.0031) and CRP > 20 mg/L (HR = 5.02, P = 0.0032)] were statistically significant for mortality. Low dose and high dose methylprednisolone were significantly associated with prolonged survival in Whites [low dose (HR = 0.37, P < 0.0001) and high dose (HR = 0.48, P < 0.0183)] and Asian/Indians [low dose (HR = 0.13, P = 0.0101) and high dose (HR = 0.15, P = 0.01)]. However, high dose was not associated with improved survival compared to low dose. Methylprednisolone was not associated with prolonged survival in Blacks and Hispanics. CONCLUSION: Racial/Ethnic disparities with inflammatory markers preclude the use of one marker as a predictor of survival. Methylprednisolone is associated with prolonged survival in Asian/Indians and Whites. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12879-022-07237-1. BioMed Central 2022-03-14 /pmc/articles/PMC8919360/ /pubmed/35287602 http://dx.doi.org/10.1186/s12879-022-07237-1 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Go, Ronaldo C.
Nyirenda, Themba
Bojarian, Maryam
Hosseini, Davood K.
Kim, Kevin
Rahim, Mehek
Paleoudis, Elli G.
Go, Anna C.
Han, Zhiyong
Sperber, Steven J.
Gupta, Anjali
Racial/ethnic disparities on inflammation and response to methylprednisolone in severe COVID-19 pneumonia
title Racial/ethnic disparities on inflammation and response to methylprednisolone in severe COVID-19 pneumonia
title_full Racial/ethnic disparities on inflammation and response to methylprednisolone in severe COVID-19 pneumonia
title_fullStr Racial/ethnic disparities on inflammation and response to methylprednisolone in severe COVID-19 pneumonia
title_full_unstemmed Racial/ethnic disparities on inflammation and response to methylprednisolone in severe COVID-19 pneumonia
title_short Racial/ethnic disparities on inflammation and response to methylprednisolone in severe COVID-19 pneumonia
title_sort racial/ethnic disparities on inflammation and response to methylprednisolone in severe covid-19 pneumonia
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8919360/
https://www.ncbi.nlm.nih.gov/pubmed/35287602
http://dx.doi.org/10.1186/s12879-022-07237-1
work_keys_str_mv AT goronaldoc racialethnicdisparitiesoninflammationandresponsetomethylprednisoloneinseverecovid19pneumonia
AT nyirendathemba racialethnicdisparitiesoninflammationandresponsetomethylprednisoloneinseverecovid19pneumonia
AT bojarianmaryam racialethnicdisparitiesoninflammationandresponsetomethylprednisoloneinseverecovid19pneumonia
AT hosseinidavoodk racialethnicdisparitiesoninflammationandresponsetomethylprednisoloneinseverecovid19pneumonia
AT kimkevin racialethnicdisparitiesoninflammationandresponsetomethylprednisoloneinseverecovid19pneumonia
AT rahimmehek racialethnicdisparitiesoninflammationandresponsetomethylprednisoloneinseverecovid19pneumonia
AT paleoudisellig racialethnicdisparitiesoninflammationandresponsetomethylprednisoloneinseverecovid19pneumonia
AT goannac racialethnicdisparitiesoninflammationandresponsetomethylprednisoloneinseverecovid19pneumonia
AT hanzhiyong racialethnicdisparitiesoninflammationandresponsetomethylprednisoloneinseverecovid19pneumonia
AT sperberstevenj racialethnicdisparitiesoninflammationandresponsetomethylprednisoloneinseverecovid19pneumonia
AT guptaanjali racialethnicdisparitiesoninflammationandresponsetomethylprednisoloneinseverecovid19pneumonia